Cynthia C. Brinson, MD

Medical Director
Central Texas Clinical Research, Austin, TX, USA

Disclosure(s): Gilead Sciences, Inc.: Grant/Research Support, Honoraria, Medical writing funds; GSK: Grant/Research Support; ViiV: Grant/Research Support

Poster(s):

• (P-364) Efficacy and Safety by Sex Assigned at Birth After Switch to Doravirine/Islatravir (100 mg/0.25 mg) Once Daily: Week 48 Results from Two Phase 3 Randomized, Active-Controlled Studies in Adults Living with HIV-1
  Monday, October 20, 2025

  12:15 PM - 1:30 PM US ET

• (P-365) Pooled safety and tolerability of twice-yearly lenacapavir with teropavimab and zinlirvimab for HIV-1 treatment
  Monday, October 20, 2025

  12:15 PM - 1:30 PM US ET